Why Were 341 Women Spending Thousands On Stress Supplements That Didn’t Work? I Posted My Receipt And Found Out.

Two stress drinks, one tincture, one gummy.

One drink contained roughly 60% of its claimed adaptogen content. The tincture’s lemon balm was undetectable. The other drink had a label discrepancy that the lab could not classify as either a sourcing error or a labeling error. The gummy is a smaller direct-to-consumer brand that markets aggressively on Instagram and uses words like clean on its packaging. Its KSM-66 content tested at 41% of label claim.

These are not the brands that probably live on your shelf. But four of 23 testing this poorly tells you something about the category as a whole. The bar is low. Some brands cannot clear it.

This is where most of the spending happens. Twelve of the 23 tested in this tier. They contain what they claim. The labels are accurate. The adaptogens are real. Every active ingredient is dosed below the level used in the studies the brands reference.

This tier includes:

Lemme Chill, which contains 300mg of KSM-66 ashwagandha. The Chandrasekhar 2012 trial that established the 27.9% cortisol reduction used 600mg per day. CNBC reported on the underdosing in 2023, with a registered dietitian publicly noting it on record. The product is not unsafe. It is half-dosed against the study it relies on for its central claim.

The mass-market gummy in the orange bottle sold in major pharmacy chains. Its GABA dose is well below the 200mg threshold associated with blood-brain barrier permeability in published research. Its L-theanine sits below the 200mg dose used in the alpha-wave studies.

The pharmacy-shelf supplement marketed as stress relief that contains 125mg of a different ashwagandha extract type than the one used in the cortisol study. The extract is fine. The dose is not the dose the research used.

The celebrity-launched aperitif drink built around a French aesthetic. Adaptogen content is real but trace.

The premium gummy from a celebrity-led pharmacy line with a price-per-serving above $1.50. KSM-66 below 400mg.

The subscription mocktail brand with a daily ritual format. Calming agents below clinical dose.

The sparkling water brand that effectively created its category. The branding is beautiful. The functional ingredients are below what published research would call therapeutic.

The tincture brand named after the thing it replaces. Real ashwagandha. Real magnesium. Sub-clinical for both.

Three smaller direct-to-consumer brands in the $30 to $45 range that all appear, by lab signature, to use the same contract manufacturer.

The front of the bottle says clinically studied or backed by research. It does not say at half the dose the study used. It is not in your blind spot. It is in everyone’s blind spot. The category designed it that way.

The reason this is happening is not malicious in any individual case. A gummy at clinical dose costs more to manufacture than a gummy at half-dose. The category has settled on the half-dose price point. The result is that you can take three different products at the recommended serving and still not hit the dose any of the studies used. You are not failing the products. The products are failing the research they are borrowing from.

That, to me, is a scam. It is a soft scam. It is an industry-wide scam. It is a scam dressed up as a category. But it is a scam.

Four products had one of the two pathways at clinical dose and the other under or missing. A direct-competitor gummy with an identity-return marketing position fell here. So did two single-ingredient capsules and a powdered drink mix.

The direct-competitor gummy in particular had a clinical dose of ashwagandha. Its GABA was below threshold. For a woman whose stress is GABA-driven, which is most women in chronic stress according to the literature, missing GABA is not a small gap. It is the gap.

One product passed potency, passed label, and had both pathways at clinical dose. One supporting active was under. It is a capsule, not a gummy. Premium price point. I am keeping the brand name out because it does not change the conclusion.

Two products passed all three tests. Both delivered both pathways at clinical dose. Both at the time windows the research used. Both with publicly available third-party COAs. Both made at FDA-registered, CGMP-certified facilities.

One is a premium capsule from a small brand at $94 per month at retail.

The other is It Girl Daily Peace.

It Girl Daily Peace was on the lab’s list because seven women in the thread had named it. I had not heard of it before this investigation. The lab opened the bottles. The lab tested them. Two products in this entire investigation passed every test. The premium capsule costs $94 a month. The gummy costs $39.99 for 28 days. The dose data is identical.

That is what the report says.

Of the 23 products tested in this investigation, two met the dose levels established by the published research the brands themselves cite. Twelve contained sub-clinical doses across every active ingredient. Four failed potency or label accuracy. The remaining five passed potency but matched clinical dose on only one of the two pathways.

The pattern is not isolated. The pattern is the category.

What this means is direct. The 18 months I spent buying stress supplements that did not work were not a failure of my body or a failure of my discipline. They were a failure of an industry to put on the front of the bottle what was actually in it. The 340 women in my comments were not failing the products either. They were buying what the marketing told them they were buying. The marketing was not the product.

Women’s Mental Wellness will continue covering this category. Tips on supplement formulation discrepancies can be sent to my editor at the address below. The full lab reports for this investigation are available on request.

If you have spent money on a product in the F, D, or C tier above, the receipt is not the indictment of you that you have been treating it as.

— L.H.

I told my editor I would not write a follow-up unless something happened that was worth telling you about. Something did.

Two weeks after this article was originally published, there was a box on my porch. A real box. Not a plastic mailer. The kind of box you set on the kitchen counter with both hands.

Inside the box was a small bouquet of white ranunculus, wrapped in brown paper and tied with twine. A six-month supply of It Girl Daily Peace, the gummy that earned an A on the lab tests. A teddy bear. A handwritten card on heavy stock that said the founder had read the article and wanted to say thank you. The handwriting was not perfect. There was a comma where there should not have been one. I noticed because I am that kind of person.

The card said the bear was for my daughter. In case she ever wants to talk to it about anything, the founder had written. Mine has heard a lot.

I sat down on a kitchen chair with the teddy bear in my hands and I cried the kind of crying you do when something hits you a half-beat after it should have. My daughter came in from the next room. I told her nothing was wrong. A nice lady sent you a bear. She took the bear. She named it Cinnamon. She has slept with it every night since.

I had not tried It Girl at the time the original article was published. The lab had tested it. I had not. It would not have been appropriate to write a six-week investigation and slip a personal endorsement into the closing. I held the line.

The package changed what was possible. The science I had learned during the investigation told me that 30 days was not enough to evaluate the cortisol pathway. KSM-66 ashwagandha takes 60 days minimum to show its effect. The brand had sent me six months. I decided I would take the full six months and write back if there was something to say.

There was.

I am not going to write another diary. The original article was a lab report, not a personal essay. So I will tell you what happened in three observations and stop.

I started sleeping through the night by the end of week one. Sleep latency improved before anything else, which is consistent with what the L-theanine and GABA studies predict in their respective time windows.

I had not slept through the night in nine months. My Oura ring told me I had not woken at 3 AM. I checked the data twice. I checked it from a different angle. I checked it on my husband’s phone in case mine was lying.

This was the smallest of the three observations. It was also the first.

The thing the KSM-66 research calls cortisol baseline reduction is, in lived experience, the thing where a hard week stops costing you the next three weeks.

By month three the bad days were no longer the indefinite drag they used to be. I had a hard Tuesday in February. I was fine by Thursday. The version of me from a year before this would have been off-kilter through the following Monday at the earliest, and probably the Wednesday after that.

The baseline did not just shift on the bad days. The baseline shifted on the recoveries.

This is what 60-plus days of clinical-dose ashwagandha actually does, in a single body, in plain language. The data in the original article said the trial showed 27.9% cortisol reduction. The 27.9% number in lived experience is recoverability. Things still happen. They stop costing as much.

My four-year-old, around month four, looked up from her coloring book and said, Mommy, you laugh more now.

I asked her what she meant.

She said, You just do.

She has said it three more times since. She has no idea I track it.

What I learned from six months on this product is not that one supplement is the answer to anything. What I learned is that I had been buying stress products at sub-clinical doses for two years and observing none of the effects published in the research. When I took a product at the doses the research used, for the time windows the research established, the effects published in the research showed up in my body.

That is not a marketing claim. That is what the data showed in my single life.

Your body is not my body. A six-month follow-up by one person is not a study.

But it is what I have.